Showing 1 - 13 results of 13 for search 'Postel-Vinay, S', query time: 0.04s
Refine Results
-
1
Refugee Settlement Around the World by André Postel-Vinay
Published 1981-10-01
Article -
2
-
3
Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments by Carine Ngo, Sophie Postel-Vinay
Published 2022-03-01
Article -
4
-
5
Beyond DNA repair: the novel immunological potential of PARP inhibitors by Roman M. Chabanon, Jean-Charles Soria, Christopher J. Lord, Sophie Postel-Vinay
Published 2019-03-01
Article -
6
-
7
A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials. by Emmanuelle Kempf, Nathalie Lemoine, Gabrielle Tergemina-Clain, Anthony Turpin, Sophie Postel-Vinay, Emilie Lanoy, Jean-Charles Soria, Christophe Massard, Antoine Hollebecque
Published 2016-01-01
Article -
8
First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to un... by Postel-Vinay, S, Herbschleb, K, Massard, C, Woodcock, V, Soria, J-C, Walter, AO, Ewerton, F, Poelman, M, Benson, N, Ocker, M, Wilkinson, G, Middleton, MR
Published 2019Journal article -
9
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA by Clémence Astier, Carine Ngo, Léo Colmet-Daage, Virginie Marty, Olivia Bawa, Claudio Nicotra, Maud Ngo-Camus, Antoine Italiano, Christophe Massard, Jean-Yves Scoazec, Cristina Smolenschi, Michel Ducreux, Antoine Hollebecque, Sophie Postel-Vinay
Published 2024-01-01
Article -
10
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial by John Hilton, Mihaela Cristea, Sophie Postel-Vinay, Capucine Baldini, Mark Voskoboynik, William Edenfield, Geoffrey I. Shapiro, Michael L. Cheng, Jacqueline Vuky, Bradley Corr, Sharmila Das, Abraham Apfel, Ke Xu, Martin Kozicki, Keziban Ünsal-Kaçmaz, Amy Hammell, Guan Wang, Palanikumar Ravindran, Georgia Kollia, Oriana Esposito, Shodeinde Coker, Jennifer R. Diamond
Published 2022-08-01
Article -
11
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines by James Campbell, Colm J. Ryan, Rachel Brough, Ilirjana Bajrami, Helen N. Pemberton, Irene Y. Chong, Sara Costa-Cabral, Jessica Frankum, Aditi Gulati, Harriet Holme, Rowan Miller, Sophie Postel-Vinay, Rumana Rafiq, Wenbin Wei, Chris T. Williamson, David A. Quigley, Joe Tym, Bissan Al-Lazikani, Timothy Fenton, Rachael Natrajan, Sandra J. Strauss, Alan Ashworth, Christopher J. Lord
Published 2016-03-01
Article -
12
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers by Capucine Baldini, Francois-Xavier Danlos, Andreea Varga, Matthieu Texier, Heloise Halse, Severine Mouraud, Lydie Cassard, Stéphane Champiat, Nicolas Signolle, Perrine Vuagnat, Patricia Martin-Romano, Jean-Marie Michot, Rastislav Bahleda, Anas Gazzah, Lisa Boselli, Delphine Bredel, Jonathan Grivel, Chifaou Mohamed-Djalim, Guillaume Escriou, Laetitia Grynszpan, Amelie Bigorgne, Saloomeh Rafie, Alae Abbassi, Vincent Ribrag, Sophie Postel-Vinay, Antoine Hollebecque, Sandrine Susini, Siham Farhane, Ludovic Lacroix, Aurelien Parpaleix, Salim Laghouati, Laurence Zitvogel, Julien Adam, Nathalie Chaput, Jean-Charles Soria, Christophe Massard, Aurelien Marabelle
Published 2022-07-01
Article -
13
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1) by Stephane Champiat, Aurélien Marabelle, Anna Spreafico, Mehmet Altan, Todd M Bauer, Osama Rahma, Karen A Autio, Neeta Somaiah, Meredith McKean, Aaron R Hansen, Jan H M Schellens, Willeke Ros, F Stephen Hodi, Jeffrey S Weber, John V Heymach, Herbert Struemper, Sandrine Aspeslagh, Daniel C Cho, Jennifer K Litton, Axel Hoos, Vincent K Lam, Emmett V Schmidt, Sophie Postel-Vinay, Frans L Opdam, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore
Published 2023-03-01
Article